List of Vesicare Ls drug patents

Vesicare Ls is owned by Astellas.

Vesicare Ls contains Solifenacin Succinate.

Vesicare Ls has a total of 1 drug patent out of which 0 drug patents have expired.

Vesicare Ls was authorised for market use on 26 May, 2020.

Vesicare Ls is available in suspension;oral dosage forms.

The generics of Vesicare Ls are possible to be released after 18 May, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9918970 ASTELLAS Pharmaceutical composition comprising solifenacin
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 26, 2023
Pediatric Exclusivity (PED) Nov 26, 2023

Drugs and Companies using SOLIFENACIN SUCCINATE ingredient

Market Authorisation Date: 26 May, 2020

Treatment: NA


How can I launch a generic of VESICARE LS before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in